Evidence map›Paper›PMID 42725039›Full record

ArticlemicroLife2026

A novel reverse lipase toxin substrate of the

Andrew B Higginson, Jasmine Soh, Stephen R Garrett, Terry K Smith, Tim R Blower, Tracy Palmer

Abstract read
In one paragraph

Article in microLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrew B HigginsonNewcastle University Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom.
Jasmine SohNewcastle University Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom.
Stephen R GarrettNewcastle University Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom.ORCID https://orcid.org/0000-0002-2101-7229
Terry K SmithBiomedical Sciences Research Complex, School of Biology, University of St. Andrews, North Haugh, St. Andrews, KY16 9ST, United Kingdom.
Tim R BlowerDepartment of Biosciences, Durham University, Durham, DH1 3LE, United Kingdom.ORCID https://orcid.org/0000-0002-7390-6458
Tracy PalmerNewcastle University Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom.ORCID https://orcid.org/0000-0001-9043-2592

Funding

Wellcome Trust
6 · The paper itself

Abstract

The type VII secretion system (T7SS) is found in many Gram-positive bacteria and secretes toxins with antibacterial activity. Most characterized substrates have an N-terminal LXG domain that interacts with other helical partner proteins to form a composite T7SS targeting signal. Here we describe only the second substrate family to have a reverse domain arrangement. We show that TslM has a C-terminal LXG-like domain and an N-terminal lipase domain that has phospholipase activity. Secretion of TslM requires a single helical partner protein that binds to the TslM C-terminus, and its toxic activity is neutralized by a distinct family of membrane proteins. Genome analysis reveals that

Indexed as

antibacterial toxinimmunity proteinlipase toxinprotein secretionStaphylococcus aureustype VII secretion

Identifiers

PMID42725039
PMCPMC13560087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.